Fig. 6

C44-Fc reduces serum TG, TC and LDL-C levels in hypercholesterolemic mice. C57BL/6 mice were induced by HF/HCCD-fed for 4 weeks to establish hypercholesterolemic mice model and then treated with isotype control Ab (25 mg/kg), C44-Fc (10 mg/kg or 25 mg/kg) and evinacumab (25 mg/kg). Serum TG (a), TC (c) and LDL-C (e) levels were tested enzymatically (n = 6–8). The TG (b), TC (d) and LDL-C (f) reduction levels of C44-Fc or evinacumab-treated group from control Ab-treated group were also measured. g Postheparin plasma LPL activities of HF/HCCD-fed mice treated with control Ab, C44-Fc and evinacumab (n = 6). h Lipid tolerance test were performed 4 days after control Ab, C44-Fc and evinacumab treatment (n = 6). †, § and * respectively represent the Student’s t-test of 10 mg/kg C44-Fc, 25 mg/kg C44-Fc and 25 mg/kg evinacumab treatment compared with control Ab